Indian Basil, popularly known as Tulsi, can be used effectively in treating patients who are exposed to radiation according to scientists at the Defense Research and Development Organization (DRDO).
The scientists are developing a herbal medicine based on the plant and will be conducting the second phase of trials to test the effectiveness of the medicine.
According to the scientists at DRDO, tulsi contains anti-oxidant properties that not only negates the ill effects of radiation, but can also be used among patients who undergo chemotherapy for cancer.
Speaking to the press, DRDO's chief controller (R&D) W Selvamurthy said that the project cost around Rs 7 crore and added that the medicine could be commercially available in the near future. "Tulsi-based medicine is already in second phase of clinical trials. It has to undergo some more trials before it is finalized and goes for commercial production. Animal trials have also been conducted and their results were quite encouraging", he said.